EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Report-Level Comparator-Definition Sensitivity in FAERS Cardiometabolic Disproportionality Analysis: A Long-Acting Cabotegravir/Rilpivirine HIV Pharmacovigilance Case Study

Shigeru Hasebe, Chihiro Nishikawa, Yuki Miura, Taiki Kusaka, Masayuki Tanaka, Shiori Iwane, Toshikazu Tsuji, Hiroyuki Kushida, Maho Kikuta

Pharmacoepidemiology · 20.08.2026 · 5 (3) · 30

DOI: 10.3390/pharma5030030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology, online erschienen am 20.08.2026. Verfasst von Shigeru Hasebe und 8 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Comparator selection can change disproportionality findings when multidrug therapies are represented by report-level listings rather than verified treatment histories. We evaluated a proxy-comparator framework for cardiometabolic reporting with long-acting cabotegravir/rilpivirine (CAB/RPV), including sensitivity to comparator definition and reporting context.

Methods

We conducted a disproportionality analysis of publicly available individual case safety reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), restricted to study-defined markets and the period from the first quarter of 2022 through the second quarter of 2025. Reports were classified as CAB/RPV, regimen-only (a complete oral regimen listing alone), or regimen-plus (that listing plus other antiretrovirals). Three contrasts assessed 3-point and expanded major adverse cardiovascular events (MACE), diabetes, dyslipidemia, and hypertension using inverse probability weighting and adjusted reporting odds ratios (aRORs). Post-review analyses examined demographic completeness, reporter source, geography, and tenofovir disoproxil fumarate (TDF) inclusion. No binary signal threshold, case-by-case review, or causality adjudication was used.

Results

The cohorts comprised 10,082 CAB/RPV, 4434 regimen-plus, and 14,559 regimen-only reports. In the internal oral contrast, regimen-plus showed statistically supported upward disproportionality for 3-point MACE (aROR 1.88, 95% confidence interval 1.44–2.15), expanded MACE (1.88, 1.47–2.40), and dyslipidemia (3.03, 2.39–3.84). CAB/RPV estimates were below 1 versus both proxies, although CAB/RPV versus regimen-plus lacked acceptable balance. Sensitivity analyses changed estimates and diagnostics; TDF inclusion left the CAB/RPV versus regimen-plus dyslipidemia estimate essentially unchanged but altered proxy-comparator findings.

Conclusions

Proxy-comparator construction influenced cardiometabolic reporting patterns; reporting-context analyses qualified their interpretation. These hypothesis-generating findings do not establish incidence, clinical risk, causal effects, comparative safety, or a protective effect.

Zitieren

APA

Hasebe, S., Nishikawa, C., Miura, Y., Kusaka, T., Tanaka, M., Iwane, S., Tsuji, T., Kushida, H., & Kikuta, M. (2026). Report-Level Comparator-Definition Sensitivity in FAERS Cardiometabolic Disproportionality Analysis: A Long-Acting Cabotegravir/Rilpivirine HIV Pharmacovigilance Case Study. Pharmacoepidemiology, 5(3), 30. https://doi.org/10.3390/pharma5030030

Vancouver

Hasebe S, Nishikawa C, Miura Y, Kusaka T, Tanaka M, Iwane S, et al. Report-Level Comparator-Definition Sensitivity in FAERS Cardiometabolic Disproportionality Analysis: A Long-Acting Cabotegravir/Rilpivirine HIV Pharmacovigilance Case Study. Pharmacoepidemiology. 2026;5(3):30. doi:10.3390/pharma5030030

BibTeX
@article{Hasebe2026,
  author = {Hasebe, Shigeru and Nishikawa, Chihiro and Miura, Yuki and Kusaka, Taiki and Tanaka, Masayuki and Iwane, Shiori and Tsuji, Toshikazu and Kushida, Hiroyuki and Kikuta, Maho},
  title = {Report-Level Comparator-Definition Sensitivity in FAERS Cardiometabolic Disproportionality Analysis: A Long-Acting Cabotegravir/Rilpivirine HIV Pharmacovigilance Case Study},
  journal = {Pharmacoepidemiology},
  year = {2026},
  volume = {5},
  number = {3},
  pages = {30},
  doi = {10.3390/pharma5030030}
}
Kostenlos starten →